Oncoproteomic profiling of AML: moving beyond genomics.
作者信息
Joshi Sunil K, Tognon Cristina E, Druker Brian J, Rodland Karin D
机构信息
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
出版信息
Expert Rev Proteomics. 2022 Jul-Dec;19(7-12):283-287. doi: 10.1080/14789450.2023.2176757. Epub 2023 Feb 10.
Abstract
摘要
相似文献
1
Oncoproteomic profiling of AML: moving beyond genomics.急性髓系白血病的肿瘤蛋白质组学分析：超越基因组学
Expert Rev Proteomics. 2022 Jul-Dec;19(7-12):283-287. doi: 10.1080/14789450.2023.2176757. Epub 2023 Feb 10.
2
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.通过不同的联合用药策略逆转FLT3突变的急性髓系白血病细胞中的获得性耐药
Clin Cancer Res. 2014 May 1;20(9):2363-74. doi: 10.1158/1078-0432.CCR-13-2052. Epub 2014 Mar 11.
3
FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.FLT3 抑制通过 FOXO 上调 HDAC8，使 p53 失活，从而促进 FLT3-ITD+ 急性髓系白血病的维持。
Blood. 2020 Apr 23;135(17):1472-1483. doi: 10.1182/blood.2019003538.
4
A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.双重抑制剂克服 FLT3-ITD 耐药性急性髓系白血病。
J Hematol Oncol. 2021 Jul 3;14(1):105. doi: 10.1186/s13045-021-01098-y.
5
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.LAM-003，一种用于治疗酪氨酸激酶抑制剂耐药的 FLT3-ITD 阳性 AML 的新药。
Blood Adv. 2019 Nov 26;3(22):3661-3673. doi: 10.1182/bloodadvances.2019001068.
6
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.米哚妥林/PKC412用于治疗新诊断的FLT3突变阳性急性髓系白血病。
Expert Rev Hematol. 2017 Dec;10(12):1033-1045. doi: 10.1080/17474086.2017.1397510. Epub 2017 Oct 30.
7
Drug resistance in mutant FLT3-positive AML.突变型 FLT3 阳性 AML 的耐药性。
Oncogene. 2010 Sep 16;29(37):5120-34. doi: 10.1038/onc.2010.273. Epub 2010 Jul 12.
8
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.FLT3 治疗靶点及其在急性髓系白血病中的相关耐药性。
J Hematol Oncol. 2020 Nov 19;13(1):155. doi: 10.1186/s13045-020-00992-1.
9
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.急性髓系白血病中的FLT3抑制剂：现状与未来方向
Mol Cancer Ther. 2017 Jun;16(6):991-1001. doi: 10.1158/1535-7163.MCT-16-0876.
10
Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.联合抑制 PI3Kδ 和 FLT3 信号通路可发挥协同抗肿瘤活性，并克服 FLT3 激活的急性髓系白血病中的获得性耐药性。
Cancer Lett. 2018 Apr 28;420:49-59. doi: 10.1016/j.canlet.2018.01.071. Epub 2018 Feb 6.
引用本文的文献
1
Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.基于质谱的蛋白质基因组学：精准医学的新治疗机会。
Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:455-479. doi: 10.1146/annurev-pharmtox-022723-113921. Epub 2023 Sep 22.
本文引用的文献
1
Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia.翻译组蛋白组学鉴定自噬是急性髓系白血病对靶标 FLT3 抑制剂产生耐药的机制。
Leukemia. 2022 Oct;36(10):2396-2407. doi: 10.1038/s41375-022-01678-y. Epub 2022 Aug 23.
2
Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance.原代 AML 患者样本的磷酸化蛋白质组学揭示了 AKT 联合治疗的原理和克服 Selinexor 耐药性的 p53 背景。
Cell Rep. 2022 Aug 9;40(6):111177. doi: 10.1016/j.celrep.2022.111177.
3
Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML.蛋白质组学和磷酸化蛋白质组学测量增强了预测急性髓系白血病离体药物反应的能力。
Clin Proteomics. 2022 Jul 27;19(1):30. doi: 10.1186/s12014-022-09367-9.
4
Proteomic and phosphoproteomic landscapes of acute myeloid leukemia.急性髓系白血病的蛋白质组学和磷酸化蛋白质组学图谱。
Blood. 2022 Sep 29;140(13):1533-1548. doi: 10.1182/blood.2022016033.
5
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.急性髓系白血病药物反应与临床结局的综合分析。
Cancer Cell. 2022 Aug 8;40(8):850-864.e9. doi: 10.1016/j.ccell.2022.07.002. Epub 2022 Jul 21.
6
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.维奈托克与吉特替尼联合应用通过抑制 MCL-1 在 FLT3 野生型高危急性髓系白血病中发挥协同作用。
Blood. 2022 Dec 15;140(24):2594-2610. doi: 10.1182/blood.2021014241.
7
The proteogenomic subtypes of acute myeloid leukemia.急性髓系白血病的蛋白质基因组亚型
Cancer Cell. 2022 Mar 14;40(3):301-317.e12. doi: 10.1016/j.ccell.2022.02.006. Epub 2022 Mar 3.
8
Cancer proteogenomics: current impact and future prospects.癌症蛋白质基因组学：当前影响与未来展望。
Nat Rev Cancer. 2022 May;22(5):298-313. doi: 10.1038/s41568-022-00446-5. Epub 2022 Mar 2.
9
Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery.蛋白质组学在癌症中的应用：生物标志物发现的最新趋势与方法
Front Med (Lausanne). 2021 Sep 22;8:747333. doi: 10.3389/fmed.2021.747333. eCollection 2021.
10
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.AML 微环境促进 gilteritinib 耐药的逐步演变。
Cancer Cell. 2021 Jul 12;39(7):999-1014.e8. doi: 10.1016/j.ccell.2021.06.003. Epub 2021 Jun 24.
Zotero 插件